1-4 of 4
Can Hekim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combining nilotinib and PD-L1 blockade reverses CD4 + T-cell dysfunction and prevents relapse in acute B-cell leukemia

Sean I. Tracy, Hrishi Venkatesh, Can Hekim, Lynn M. Heltemes-Harris, Todd P. Knutson, Veronika Bachanova, Michael A. Farrar
Journal: Blood
Blood (2022) 140 (4): 335–348.
https://doi.org/10.1182/blood.2021015341
Published: 2022
Includes: Supplemental data
Journal Articles

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

Sean I. Tracy, MD PhD, Can Hekim, MSc,PhD, Michael Farrar, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1345.
https://doi.org/10.1182/blood-2019-124205
Published: 2019
Journal Articles

Overcoming Leukemia-Induced Immune Suppression in BCR-ABL+ Acute Lymphoblastic Leukemia

Michael Farrar, PhD, Can Hekim, MSc,PhD, Manlove S. Luke, PhD, Vaiva Vezys, PhD, Marc K Jenkins, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3881.
https://doi.org/10.1182/blood.V130.Suppl_1.3881.3881
Published: 2017
Journal Articles

Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model

Mette Matilda Ilander, MSc, Can Hekim, PhD, Markus Vähä-Koskela, PhD, Paula Savola, Siri Tähtinen, MSc, Leena Saikko, Akseli Hemminki, MDPhD, Panu Kovanen, MDPhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD
Journal: Blood
Blood (2014) 124 (21): 1408.
https://doi.org/10.1182/blood.V124.21.1408.1408
Published: 2014